Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. IFRX
IFRX logo

IFRX Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy InflaRx NV (IFRX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
0.930
1 Day change
52 Week Range
1.940
Analysis Updated At
2026/03/06
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

InflaRx NV (IFRX) is not a good buy for a long-term beginner investor at this time. The company's financial performance is significantly declining, with sharp drops in revenue, net income, and EPS. Additionally, there are no strong positive catalysts or trading signals to support a buy decision. The technical indicators and options data suggest a neutral to slightly bearish sentiment, and the lack of recent news or influential trading activity further weakens the case for investment.

Technical Analysis

The MACD is slightly positive at 0.0113 but contracting, indicating weakening momentum. The RSI is neutral at 60.485, and moving averages are converging, suggesting no clear trend. Key support and resistance levels are at 0.85 and 0.949, respectively, with the stock trading pre-market at 0.93, close to resistance. Overall, the technical indicators do not strongly support a buy decision.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

The low put-call ratios indicate a lack of bearish sentiment, but the overall low volume and open interest suggest limited activity and interest in the stock.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
5
Buy
3

Positive Catalysts

  • Hedge funds have increased their buying activity by 425.33% over the last quarter, which may indicate some institutional interest.

Neutral/Negative Catalysts

  • The company's financial performance has significantly declined in the latest quarter, with revenue dropping by -80.75% YoY, net income down -29.73% YoY, and EPS down -40% YoY. Additionally, there is no recent news, analyst updates, or influential trading activity to provide support for the stock.

Financial Performance

In Q3 2025, revenue dropped to 23,830 (-80.75% YoY), net income fell to -12,261,089 (-29.73% YoY), EPS decreased to -0.18 (-40% YoY), and gross margin declined to 98.6 (-37.83% YoY). These figures indicate significant financial struggles.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent updates on analyst ratings or price targets are available for IFRX.

Wall Street analysts forecast IFRX stock price to rise
8 Analyst Rating
Wall Street analysts forecast IFRX stock price to rise
6 Buy
2 Hold
0 Sell
Strong Buy
Current: 0.930
sliders
Low
6
Averages
12.67
High
24
Current: 0.930
sliders
Low
6
Averages
12.67
High
24
Leerink
Outperform -> Market Perform
downgrade
$2
AI Analysis
2025-12-03
Reason
Leerink
Price Target
$2
AI Analysis
2025-12-03
downgrade
Outperform -> Market Perform
Reason
Leerink downgraded InflaRx to Market Perform from Outperform with a $2 price target.
Leerink
Joseph Schwartz
Outperform -> Market Perform
downgrade
$5 -> $2
2025-12-03
Reason
Leerink
Joseph Schwartz
Price Target
$5 -> $2
2025-12-03
downgrade
Outperform -> Market Perform
Reason
Leerink analyst Joseph Schwartz downgraded InflaRx to Market Perform from Outperform with a price target of $2, down from $5. InflaRx delivered unexpectedly positive Phase 2a data for INF904 in Hidradenitis Suppurativa and Chronic Spontaneous Urticaria, with the HS results looking compelling enough to justify a Phase 2b trial, the analyst tells investors in a research note. Despite management's view that its EUR 44.4M cash balance can fund operations into 2027, further financing appears likely and could be notably dilutive at the current valuation.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for IFRX
Unlock Now

People Also Watch